Celldex Therapeutics
Clinical trials sponsored by Celldex Therapeutics, explained in plain language.
-
New shot could ease swallowing for eosinophilic esophagitis patients
Disease control CompletedThis phase 2 trial tested a biologic drug called barzolvolimab in 86 adults with active eosinophilic esophagitis, a condition that causes trouble swallowing due to inflammation in the esophagus. Participants received either the drug or a placebo as a shot under the skin. The stud…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New shot could tame stubborn hives that antihistamines Can't stop
Disease control CompletedThis Phase 2 study tested a drug called barzolvolimab (CDX-0159) in 196 adults with chronic inducible urticaria—hives triggered by cold or scratching—that persist despite antihistamines. Participants received either the drug or a placebo as a shot under the skin. The main goal wa…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug CDX-622 tested for safety in healthy people
Knowledge-focused CompletedThis completed Phase 1 trial tested the safety of a new drug called CDX-622 in 85 healthy adults aged 18-55. Participants received either CDX-622 or a placebo (saline) by infusion or injection. The study measured side effects, drug levels in the blood, and immune responses. Since…
Phase: PHASE1 • Sponsor: Celldex Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC